Sprint Bioscience

The evaluation has now been concluded, and while the findings did not support advancing the molecules into another inflammatory indication at this time, the collaboration generated valuable scientific insights, which further strengthen Sprint Bioscience’s understanding of the program and reinforce the company’s strategic focus on MASH as the lead indication.

" The evaluation provided important learnings that help sharpen our long‑term development strategy,” said Johan Emilsson, CEO at Sprint Bioscience. “We appreciate the strong scientific partnership with EDDC and the commitment they have shown throughout the process.”

“Our partnership with Sprint has been marked by openness and a collaborative spirit, and we are thankful for the opportunity to work together on this evaluation. We hope the knowledge generated through this project will support future efforts to deliver meaningful impact for patients,” said Damian O’Connell, CEO of EDDC.

The MASH program remains a valuable asset in Sprint Bioscience’s R&D pipeline. Supported by encouraging MASH data, the company remains committed to advancing this potential therapy for patients with high unmet medical need and will continue to dedicate resources to advance the program.

Sprint Bioscience extends its gratitude to the team at EDDC for their resources and collaborative spirit throughout this evaluation.

MASH (metabolic dysfunction-associated steatohepatitis) is a progressive form of fatty liver disease linked to conditions such as obesity and type 2 diabetes. It involves liver inflammation and cellular damage that may result in fibrosis, cirrhosis, or liver failure. Sprint Bioscience’s MASH program offers a novel and complementary mechanism of action alongside existing therapies. With rising diagnosis rates and greater disease awareness, the addressable patient population continues to expand.